We have added the following three drugs to the Possible Risk (PR) of TdP category due to evidence that they are associated with QT prolongation when taken at clinically recommended doses.
Primaquine (anti-malarial)
Fluorouracil (anti-cancer)
Lopinavir/Ritonavir combination (Anti-viral)
Because of limited evidence for an association with torsades de pointes, we have removed ritonavir as a single ingredient formulation from the Conditional Risk (CR) list.
Remember the Smartphone apps for CredibleMeds gives you immediate free access to the most up-to-date list of drugs that are associated with QT prolongation and/or torsades de pointes.
Loading Conversation